Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Ashruf, O
If you are enrolled in such a trial, all reconstitution, storage, and stability questions must be directed to your trial site team or the trial pharmacy
They did such an amazing job
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
US$ 26.54
US$ 20.38
US$ 21.92
US$ 21.63
US$ 22.56
US$ 24.91
US$ 27.50
US$ 20.84
